TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00281879

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: anti-thymocyte globulin
Description: Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.
Study: NCT02778230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Fiber
Description: Snacks (2 baked goods) fortified with 5 g pea hull fiber
Study: NCT01733017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sodium reduction
Description: Teaching and skill building to reduce dietary sodium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega 3 and lycopene supplements
Description: omega-3 fatty acid supplements and juices containing lycopene

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: rice bran oil capsules
Description: placebo capsules

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Generic dietary feedback from
Description: Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
Study: NCT01462266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg tablet once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to sitagliptin once daily for 24 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Glargine
Description: Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
Study: NCT03110900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol + lorazepam
Description: Haloperidol + lorazepam + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxapine
Description: loxapine + placebo
Study: NCT04069845

Intervention type: DRUG
Intervention: liposomal doxorubicin
Description: intravenous liposomal doxorubicin
Study: NCT01489527

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil Vaccine
Description: The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
Study: NCT00612638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar, O6-BG, and Irinotecan
Description: 2 separate strata accrued independently: Stratum 1-pts receiving Dilantin, Tegretol or phenobarbital. Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants. O6-BG administered intravenously 120mg/m2, over 1hr, prior to administration of Temozolomide on day 1 of 21day cycle. O6-BG administered intravenously 30mg/m2/day, over 48hrs, immediately after completion of CPT-11 infusion on day 1 of 21-day cycle. Temozolomide administered orally 355mg/m2 within 60 mins of end of 1hr O6-BG infusion. Treatment cycles may be repeated every 3wks following dose of Temozolomide from previous cycle. CPT-11 administered intravenously in fasting state over 90mins. CPT-11 infusion will begin 1hr after Temozolomide administration. Initial doses 60mg/m2 for stratum 1 \& 40mg/m2 for stratum2. Treatment cycles repeated every 3 wks following dose of CPT-11 from previous cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar, O6-BG, and Irinotecan
Description: 2 separate strata accrued independently: Stratum 1-pts receiving Dilantin, Tegretol or phenobarbital. Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants. O6-BG administered intravenously 120mg/m2, over 1hr, prior to administration of Temozolomide on day 1 of 21day cycle. O6-BG administered intravenously 30mg/m2/day, over 48hrs, immediately after completion of CPT-11 infusion on day 1 of 21-day cycle. Temozolomide administered orally 355mg/m2 within 60 mins of end of 1hr O6-BG infusion. Treatment cycles may be repeated every 3wks following dose of Temozolomide from previous cycle. CPT-11 administered intravenously in fasting state over 90mins. CPT-11 infusion will begin 1hr after Temozolomide administration. Initial doses 60mg/m2 for stratum 1 \& 40mg/m2 for stratum2. Treatment cycles repeated every 3 wks following dose of CPT-11 from previous cycle.
Study: NCT02381119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Dietary Advice Services
Description: This Personalized Dietary Advice is based on markers for nutrition status and SNPs (single nucleotide polymorphisms).~This advice is given via Personalized Dietary Advice Services, in which health data of the client can be entered and will be translated into advice on intake of specific nutrients or food categories.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: The control group will receive usual advice for diabetes type 2 from the dietician. However, after the end of the study participants in the control group will be offered the opportunity to receive the Personalized Dietary Advice from their dietician, as based on the parameters measured during the study.
Study: NCT01910714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus On Youth
Description: Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control Condition
Description: The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
Study: NCT01261156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555 100 mg and diltiazem
Description: E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555 300 mg and diltiazem
Description: E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
Study: NCT01088035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
Study: NCT04057339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating + Standard of Care
Description: Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietitian.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 8-10-hr eating window.
Study: NCT03439150

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Absolute flow and resistance measurement
Description: Absolute flow and resistance measurements immediately after PPCI of the culprit vessel (in a STEMI setting) and repeated absolute flow and resistance measurements after 3-7 days
Study: NCT00993746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus lidocaine
Description: Bupivacaine 20 ml plus lidocaine 10 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 30 ml
Description: Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
Study: NCT01031446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Taken daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood collection
Study: NCT02037659

Intervention type: PROCEDURE
Intervention: DermaBond treatment of Gastric Varices
Description: Endoscopic Ultrasound (EUS) administration of DermaBond glue to control bleeding gastric varices.
Study: NCT01845038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TPa ~4µg/day over 2 mos. with natural tears drops
Description: OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of \~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TPb ~3µg/day over 3 months with natural tears drops
Description: OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of \~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug
Description: Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
Study: NCT05932550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: 10 week treatment as add-on therapy to anti-depressants
Study: NCT01476787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-CHOP
Description: 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-CVP
Description: 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-Bendamustine
Description: 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Study: NCT02403609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPT, Computerized Assessment
Study: NCT02544932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran
Description: After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribaroxaban
Description: After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
Study: NCT02542709

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive Transcranial Magnetic Stimulation
Description: Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation
Description: Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
Study: NCT04797832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Sodium Ferric Gluconate Complex
Description: 125 mg of IV Iron per day to 3 to 5 days according to hospitalisation length.
Study: NCT02901288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin is a widely used anti-tuberculosis medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin is a widely used anti-tuberculosis medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin is a widely used anti-tuberculosis medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
Study: NCT00692211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed fecal occult blood tests
Description: Stool blood test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed fecal immunochemical tests
Description: Stool blood test
Study: NCT02135887

Intervention type: DRUG
Intervention: MB-6
Description: 6# TID with meal

Intervention type: DRUG
Intervention: Placebo
Description: 6# TID with meal
Study: NCT01547325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDOX 1% doxycycline monohydrate Hydrogel
Description: 1% doxycycline monohydrate hydrogel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo hydrogel
Description: placebo hydrogel
Study: NCT01317342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermic oxygenated perfusion (HOPE)
Description: Application of HOPE for 1 hour, perfusion rate 150-300 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate Institute George Lopez solution (IGL-1), perfusate temperature 4-6 °C, perfusate oxygenation 150-200 mm Hg
Study: NCT05280678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic miniscrew insertion in the mandibular buccal shelf
Description: Each patient received miniscrews in both sizes. The same orthodontist (M.S.) performed all the insertion procedures. Miniscrews were always placed in the mandibular buccal shelf, laterally to the first and second molar interproximal area, with angulation 30 degree to the bone surface, meaning that miniscrew angulation should be approximately the same as the axial inclination of the adjacent molar. Miniscrews were loaded with orthodontic force 2 weeks after the surgery. The investigated factors were:~* long-term success rate of the miniscrews in the buccal shelf of the mandible (miniscrews were considered long-term stable if they served as an anchorage until completion of mandibular distalization, at least 9 months);~* peri-implantitis development (enlargement of the gingiva and/or redness and/or tendency to bleed);~* the patient's report of pain lasting longer than 48 hours after miniscrew insertion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic miniscrew insertion in the mandibular buccal shelf
Description: Each patient received miniscrews in both sizes. The same orthodontist (M.S.) performed all the insertion procedures. Miniscrews were always placed in the mandibular buccal shelf, laterally to the first and second molar interproximal area, with angulation 30 degree to the bone surface, meaning that miniscrew angulation should be approximately the same as the axial inclination of the adjacent molar. Miniscrews were loaded with orthodontic force 2 weeks after the surgery. The investigated factors were:~* long-term success rate of the miniscrews in the buccal shelf of the mandible (miniscrews were considered long-term stable if they served as an anchorage until completion of mandibular distalization, at least 9 months);~* peri-implantitis development (enlargement of the gingiva and/or redness and/or tendency to bleed);~* the patient's report of pain lasting longer than 48 hours after miniscrew insertion.
Study: NCT02708953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation (Manipulation Group)
Description: Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Manipulation (Control wait-list)
Description: Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
Study: NCT04124146

Intervention type: RADIATION
Intervention: MRI for some patients according functionnal tests results
Description: Depending on the results obtained on the evaluation criteria, additional examinations could be prescribed (imaging) for subjects with an unsatisfactory functional score. There is therefore a potential change in the usual care.